10x Genomics’ (TXG) Sell (E+) Rating Reiterated at Weiss Ratings

10x Genomics (NASDAQ:TXG)‘s stock had its “sell (e+)” rating restated by analysts at Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.

A number of other equities analysts have also weighed in on the company. Morgan Stanley decreased their price target on 10x Genomics from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, January 13th. Canaccord Genuity Group lowered their price target on shares of 10x Genomics from $32.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, October 10th. UBS Group dropped their price objective on 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th. The Goldman Sachs Group reduced their target price on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research note on Wednesday, October 30th. Finally, Barclays decreased their target price on shares of 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.86.

10x Genomics Price Performance

Shares of NASDAQ TXG traded down $0.01 during mid-day trading on Friday, reaching $15.08. 1,324,480 shares of the company traded hands, compared to its average volume of 1,475,648. 10x Genomics has a fifty-two week low of $12.95 and a fifty-two week high of $51.22. The stock has a fifty day simple moving average of $14.96 and a 200-day simple moving average of $17.95. The firm has a market cap of $1.83 billion, a PE ratio of -9.86 and a beta of 1.83.

10x Genomics (NASDAQ:TXG) last released its earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The firm had revenue of $151.65 million for the quarter, compared to analyst estimates of $158.84 million. During the same period in the previous year, the company earned ($0.51) earnings per share. 10x Genomics’s revenue was down 1.3% compared to the same quarter last year. As a group, analysts predict that 10x Genomics will post -1.43 EPS for the current fiscal year.

Institutional Investors Weigh In On 10x Genomics

A number of institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in 10x Genomics by 451.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock valued at $35,000 after purchasing an additional 1,265 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in shares of 10x Genomics during the third quarter worth $35,000. Blue Trust Inc. increased its stake in shares of 10x Genomics by 136.5% in the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after buying an additional 1,025 shares in the last quarter. Sound Income Strategies LLC bought a new position in shares of 10x Genomics in the third quarter valued at about $46,000. Finally, Venturi Wealth Management LLC raised its holdings in shares of 10x Genomics by 1,108.9% in the third quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock valued at $55,000 after buying an additional 2,240 shares during the last quarter. 84.68% of the stock is owned by institutional investors and hedge funds.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.